<DOC>
	<DOCNO>NCT00792623</DOCNO>
	<brief_summary>This study aim assess immunogenicity safety varicella vaccination population autologous peripheral stem cell/ bone marrow transplantation recipient reach least four month post-transplantation .</brief_summary>
	<brief_title>Immunogenicity Safety GSK Biologicals ' Live Attenuated Varicella Vaccine ( VARILRIXTM ) .</brief_title>
	<detailed_description />
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<criteria>Screening phase : A male female â‰¥ 18 year age time study entry . Written inform consent obtain subject prior study entry . Patients plan undergo autologous peripheral stem cell/ bone marrow transplantation . Subjects investigator believe comply requirement protocol If subject female , must nonchildbearing potential ; , childbearing potential , must abstinent use adequate contraceptive precaution 30 day prior vaccination , negative pregnancy test must agree continue precaution 10 month transplantation . Active phase : Patients confirm undergone autologous peripheral stem cell/ bone marrow transplantation . If subject female , must nonchildbearing potential ; , childbearing potential , must abstinent use adequate contraceptive precaution 30 day prior vaccination , negative pregnancy test must agree continue precaution 10 month transplantation . Screening phase : Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution 10 month posttransplantation . History allergy component vaccine . Patients difficult treat disease likely relapse within 6 month posttransplantation . Current drug and/or alcohol abuse . Active phase : Use investigational nonregistered product ( drug vaccine ) active phase study period . Use immunosuppressant immunemodifying drug within 14 day precede administration first dose study vaccine plan use active phase study period . Use rituximab ( MabThera ) 60 day transplant . Administration vaccine foreseen study protocol period start 30 day dose vaccine end 30 day . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution 10 month posttransplantation . History allergy component vaccine Patients VZV disease transplantation prior vaccination . Ongoing requirement antiviral therapy antiVZV activity beyond 4 month posttransplantation Patients difficult treat disease likely relapse within 6 month posttransplantation . Current drug and/or alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Varicella</keyword>
	<keyword>VarilrixTM</keyword>
</DOC>